Stories that are getting the most attention from our readers in the last 24 hours.
A randomized controlled phase 3 trial enrolled 316 patients with newly diagnosed glioblastoma multiforme, an aggressive brain cancer. After standard surgery and radiation, participants received either personalized mRNA vaccines designed from sequencing their tumor mutations or standard care alone. The vaccine group showed a median survival extension of 9 months compared to controls. This breakthrough, published in Nature Medicine on March 7, 2026, highlights precision oncology's potential to improve outcomes in a disease with historically dismal prognosis of about 15 months median survival.
A multicenter phase 3 randomized controlled trial enrolled 420 patients with advanced melanoma who had progressed after prior checkpoint inhibitor therapy, randomly assigning them to receive either the novel bispecific T-cell engager antibody targeting PD-1 and LAG-3 or standard chemotherapy. Responses were evaluated using RECIST criteria, with primary endpoints including objective response rate and progression-free survival. The antibody group achieved a 65% objective response rate, with many responses lasting over 12 months, significantly outperforming chemotherapy. This positions the treatment as a potential second-line option, reducing reliance on toxic chemotherapies and improving outcomes for refractory patients. Published in Nature Medicine on March 7, 2026.
We use cookies to analyze site traffic and improve your experience. By clicking Accept, you consent to our use of analytics cookies. Privacy Policy